Vor Bio To Participate In The Stifel 2025 Virtual Immunology And Inflammation Forum

2025-09-12 04:16:16

(MENAFN- GlobeNewsWire - Nasdaq) CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the Stifel 2025 Virtual Immunology and Inflammation Forum.

Fireside Chat: Monday, September 15, 2025 at 4:00-4:25 pm ET in Track 1
Location: Virtual

A live webcast and archived replay of the fireside chat will be available on the Company's website at:

About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and commercialization to address serious autoantibody-driven conditions worldwide. For more information visit .

Media & Investor Contacts:
Carl Mauch
...

Sarah Spencer
...

MENAFN12092025004107003653ID1110055308

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.